Ceralasertib

Ceralasertib
Clinical data
Other names	AZD-6738
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane;
CAS Number	1352226-88-0;
PubChem CID	54761306;
IUPHAR/BPS	9390;
DrugBank	DB14917;
ChemSpider	58828171;
UNII	85RE35306Z;
KEGG	D11787;
ChEMBL	ChEMBL4285417;
PDB ligand	VJM (PDBe, RCSB PDB);
ECHA InfoCard	100.232.607
Chemical and physical data
Formula	C20H24N6O2S
Molar mass	412.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4;
	InChI InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1; Key:OHUHVTCQTUDPIJ-JYCIKRDWSA-N;

Ceralasertib is an investigational new drug that is being evaluated for the treatment of cancer.^[1] It is an ATR kinase inhibitor.^[2]

References

^ "Ceralasertib - AstraZeneca/University of Pennsylvania". AdisInsight. Springer Nature Switzerland AG.
^ Mavroeidi D, Georganta A, Panagiotou E, Syrigos K, Souliotis VL (February 2024). "Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes". International Journal of Molecular Sciences. 25 (5): 2767. doi:10.3390/ijms25052767. PMC 10932434. PMID 38474014.